Contributions
Abstract: 157
Type: Oral
A genomics approach provides the possibility of describing biomarkers associated with biologic-treatment-related progressive multifocal leucoencephalopathy (PML). If successful, this will be a major advance for patients.
Starting in 2007 we prospectively built up a cohort of 1200 patients treated with natalizumab (NTZ), with their clinical and radiological data, plus biological samples. Fourteen patients experienced PML. We also collected 21 additional NTZ-related PML. Thanks to the study design, we were able to work with almost 40 pre-PML biological samples, performing exome sequencing (Library = SureSelectXTTM Human All Exon V5 (Agilent) / Sequencing= HiSeq sequencer Illumina ), HLA sequencing (Illumina MySEQ ), RNA sequencing (Illumina) and cytokine multiplex quantitation (Luminex), and analysing circulating miRNA (Affymetrix® GeneChip® microarrays), methylone (Human Methylation 450 Illumina) and blood bacterial 16S ribosomal RNA (Vaiomer) on these samples within the best-MS network (a FP7-2012 project).
We present a compilation of the pros and cons of our approach.
Disclosure: DB received support for travel to meetings, fees for participation in board or lecture with Biogen, Merck, Novartis, and Teva
Abstract: 157
Type: Oral
A genomics approach provides the possibility of describing biomarkers associated with biologic-treatment-related progressive multifocal leucoencephalopathy (PML). If successful, this will be a major advance for patients.
Starting in 2007 we prospectively built up a cohort of 1200 patients treated with natalizumab (NTZ), with their clinical and radiological data, plus biological samples. Fourteen patients experienced PML. We also collected 21 additional NTZ-related PML. Thanks to the study design, we were able to work with almost 40 pre-PML biological samples, performing exome sequencing (Library = SureSelectXTTM Human All Exon V5 (Agilent) / Sequencing= HiSeq sequencer Illumina ), HLA sequencing (Illumina MySEQ ), RNA sequencing (Illumina) and cytokine multiplex quantitation (Luminex), and analysing circulating miRNA (Affymetrix® GeneChip® microarrays), methylone (Human Methylation 450 Illumina) and blood bacterial 16S ribosomal RNA (Vaiomer) on these samples within the best-MS network (a FP7-2012 project).
We present a compilation of the pros and cons of our approach.
Disclosure: DB received support for travel to meetings, fees for participation in board or lecture with Biogen, Merck, Novartis, and Teva